Who is sponsoring NCT02211872?

NCT02211872 is sponsored by Boehringer Ingelheim.

What drugs are being tested in NCT02211872?

Interventions: BI 2536 BS, intravenous.

What is the status of NCT02211872?

NCT02211872 is currently COMPLETED.

Last reviewed 2014-08-07 · How we verify

An Open Phase I Single Dose Escalation Study of BI 2536 BS Administered Intravenously in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit

NCT02211872 Phase 1 COMPLETED

The primary objective of this study was to determine the maximum tolerated dose (MTD) of BI 2536 BS in patients with advanced solid tumours. Secondary objectives were the evaluation of safety, efficacy, and pharmacokinetics of BI 2536 BS

Details

Lead sponsor	Boehringer Ingelheim
Phase	Phase 1
Status	COMPLETED
Enrolment	63
Start date	2004-08

Conditions

Neoplasms

Interventions

BI 2536 BS, intravenous

Primary outcomes

Maximum tolerated dose (MTD) for a single dose of BI 2536 BS — Up to 16 weeks
MTD for single doses of BI 2536 BS on 3 consecutive days — Up to 16 weeks